• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一种作用于靶点的囊性纤维化新疗法：半胱胺加表没食子儿茶素没食子酸酯用于自噬依赖性拯救II类突变型囊性纤维化跨膜传导调节因子。

A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.

作者信息

Tosco A, De Gregorio F, Esposito S, De Stefano D, Sana I, Ferrari E, Sepe A, Salvadori L, Buonpensiero P, Di Pasqua A, Grassia R, Leone C A, Guido S, De Rosa G, Lusa S, Bona G, Stoll G, Maiuri M C, Mehta A, Kroemer G, Maiuri L, Raia V

出版信息

Cell Death Differ. 2017 Jul;24(7):1305. doi: 10.1038/cdd.2016.43. Epub 2016 Jul 22.

DOI:10.1038/cdd.2016.43
PMID:27447111
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5520161/
Abstract

This corrects the article DOI: 10.1038/cdd.2016.22.

摘要

本文更正了文章的数字对象标识符

10.1038/cdd.2016.22 。

相似文献

1
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.一种作用于靶点的囊性纤维化新疗法：半胱胺加表没食子儿茶素没食子酸酯用于自噬依赖性拯救II类突变型囊性纤维化跨膜传导调节因子。
Cell Death Differ. 2017 Jul;24(7):1305. doi: 10.1038/cdd.2016.43. Epub 2016 Jul 22.
2
A novel treatment of cystic fibrosis acting on-target: cysteamine plus epigallocatechin gallate for the autophagy-dependent rescue of class II-mutated CFTR.一种作用于靶点的囊性纤维化新疗法：半胱胺加表没食子儿茶素没食子酸酯用于自噬依赖性拯救II类突变型囊性纤维化跨膜传导调节因子
Cell Death Differ. 2016 Aug;23(8):1380-93. doi: 10.1038/cdd.2016.22. Epub 2016 Apr 1.
3
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.携带F508del-CFTR突变的囊性纤维化患者CFTR功能的恢复。
Autophagy. 2014;10(11):2053-74. doi: 10.4161/15548627.2014.973737.
4
Evaluation of autophagy inducers in epithelial cells carrying the ΔF508 mutation of the cystic fibrosis transmembrane conductance regulator CFTR.评估囊性纤维化跨膜电导调节因子 CFTR 携带 ΔF508 突变的上皮细胞中的自噬诱导剂。
Cell Death Dis. 2018 Feb 7;9(2):191. doi: 10.1038/s41419-017-0235-9.
5
Metabolic interactions between cysteamine and epigallocatechin gallate.半胱胺与表没食子儿茶素没食子酸酯之间的代谢相互作用。
Cell Cycle. 2017 Feb;16(3):271-279. doi: 10.1080/15384101.2016.1249550. Epub 2017 Jan 6.
6
Dendrimer-based selective autophagy-induction rescues ΔF508-CFTR and inhibits Pseudomonas aeruginosa infection in cystic fibrosis.基于树枝状大分子的选择性自噬诱导可挽救ΔF508-CFTR并抑制囊性纤维化中的铜绿假单胞菌感染。
PLoS One. 2017 Sep 13;12(9):e0184793. doi: 10.1371/journal.pone.0184793. eCollection 2017.
7
Nano-based rescue of dysfunctional autophagy in chronic obstructive lung diseases.基于纳米技术对慢性阻塞性肺疾病中功能失调自噬的挽救作用
Expert Opin Drug Deliv. 2017 Apr;14(4):483-489. doi: 10.1080/17425247.2016.1223040. Epub 2016 Aug 26.
8
Novel cystamine-core dendrimer-formulation rescues ΔF508-CFTR and inhibits Pseudomonas aeruginosa infection by augmenting autophagy.新型半胱胺核心树枝状大分子制剂通过增强自噬来拯救 ΔF508-CFTR 并抑制铜绿假单胞菌感染。
Expert Opin Drug Deliv. 2019 Feb;16(2):177-186. doi: 10.1080/17425247.2019.1575807. Epub 2019 Feb 7.
9
Bioactivity-guided fractionation of an antidiarrheal Chinese herb Rhodiola kirilowii (Regel) Maxim reveals (-)-epicatechin-3-gallate and (-)-epigallocatechin-3-gallate as inhibitors of cystic fibrosis transmembrane conductance regulator.对止泻中药红景天进行生物活性导向的分离，发现（-）-表儿茶素-3-没食子酸酯和（-）-表没食子儿茶素-3-没食子酸酯是囊性纤维化跨膜传导调节因子的抑制剂。
PLoS One. 2015 Mar 6;10(3):e0119122. doi: 10.1371/journal.pone.0119122. eCollection 2015.
10
Autophagy suppresses the pathogenic immune response to dietary antigens in cystic fibrosis.自噬抑制囊性纤维化中膳食抗原的致病性免疫反应。
Cell Death Dis. 2019 Mar 15;10(4):258. doi: 10.1038/s41419-019-1500-x.

引用本文的文献

1
Inhibition of macrophages inflammasome activation autophagic degradation of HMGB1 by EGCG ameliorates HBV-induced liver injury and fibrosis.EGCG 通过抑制巨噬细胞炎性小体激活自噬降解 HMGB1 减轻乙型肝炎病毒诱导的肝损伤和纤维化。
Front Immunol. 2023 Apr 14;14:1147379. doi: 10.3389/fimmu.2023.1147379. eCollection 2023.
2
Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.具有体外抗病毒活性和免疫调节作用的半胱胺有可能成为治疗 COVID-19 的重新定位药物候选物。
Cells. 2021 Dec 24;11(1):52. doi: 10.3390/cells11010052.
3
Dysfunctional Inflammation in Cystic Fibrosis Airways: From Mechanisms to Novel Therapeutic Approaches.囊性纤维化气道中的功能失调性炎症：从机制到新的治疗方法。
Int J Mol Sci. 2021 Feb 16;22(4):1952. doi: 10.3390/ijms22041952.
4
Transcriptomic and Proteostasis Networks of CFTR and the Development of Small Molecule Modulators for the Treatment of Cystic Fibrosis Lung Disease.CFTR 的转录组和蛋白质稳定网络，以及小分子调节剂治疗囊性纤维化肺病的开发。
Genes (Basel). 2020 May 13;11(5):546. doi: 10.3390/genes11050546.
5
Silencing of the Hsp70-specific nucleotide-exchange factor BAG3 corrects the F508del-CFTR variant by restoring autophagy.通过恢复自噬，抑制热休克蛋白 70 特异性核苷酸交换因子 BAG3 可纠正 F508del-CFTR 变体。
J Biol Chem. 2018 Aug 31;293(35):13682-13695. doi: 10.1074/jbc.RA118.002607. Epub 2018 Jul 9.
6
microRNA-181b is increased in cystic fibrosis cells and impairs lipoxin A receptor-dependent mechanisms of inflammation resolution and antimicrobial defense.miR-181b 在囊性纤维化细胞中增加，并损害脂氧素 A 受体依赖的炎症解决和抗菌防御机制。
Sci Rep. 2017 Oct 18;7(1):13519. doi: 10.1038/s41598-017-14055-y.